The North Carolina Utilities Commission issued written orders approving comprehensive revenue requirement settlements for Duke Energy Carolinas and Duke Energy Progress. The orders approve a 9.8% return on equity and retail rate bases totaling approximately $43.5 billion across both entities. Revised customer rates are expected to be implemented effective January 1, 2027.
Tonix Pharmaceuticals filed a patent infringement lawsuit against Dr. Reddy’s Laboratories in the U.S. District Court for the District of New Jersey following a Paragraph IV certification regarding TONMYA®. The filing of the complaint triggers a statutory 30-month stay of final FDA approval for Dr. Reddy’s proposed generic version of the drug. Tonix seeks to prevent generic competition until the expiration of its Orange Book-listed patents.
The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.
Skye Bioscience received a unanimous jury verdict in its favor following a retrial in the U.S. District Court for the Central District of California. The lawsuit, filed by a former employee, alleged whistleblower protection violations and retaliation related to events occurring between 2018 and 2019. The verdict clears the company of all claims, though the plaintiff retains the right to file post-trial motions or appeals.
Lamb Weston, Inc., a subsidiary of Lamb Weston Holdings, Inc., entered into a $25 million settlement agreement to resolve a putative class action lawsuit regarding groundwater nitrate levels in Oregon. The settlement fund will provide property enhancements and water filtration systems for residents, with payment expected in the second half of fiscal year 2027 subject to court approval.
Counterparty
Private plaintiffs in the U.S. District Court for the District of Oregon
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
KULR Technology Group filed a verified petition in the Delaware Court of Chancery under Section 205 of the DGCL to validate certain past corporate acts and its outstanding capitalization. The company identified technical failures in authorizing a 2016 name change, a 2018 increase in authorized common stock, and the designation of its Series A Preferred Stock, which it cannot ratify through standard procedures due to the disparate holding of putative shares.
HyOrc Corporation entered into a settlement agreement to resolve litigation in Nevada with Daniel S. McKinney and Coldway Limited, LLC. The lawsuit, which sought damages in excess of $3 million, concerned the affiliate/control classification of the plaintiffs on the company's transfer agent records. The settlement involves no monetary payment by any party and includes a mutual release of claims and the dismissal of the action with prejudice.
Aeries Technology entered into a settlement agreement with Sea Otter Trading, LLC to resolve outstanding obligations under a previously amended Forward Purchase Agreement. The company will pay $911,461 in exchange for the return of 145,183 Class A ordinary shares held as collateral, effectively terminating the prior transaction agreements.
3M entered into a $7.35 billion nominal settlement ($5.8 billion present value) to resolve the vast majority of PFAS-related personal injury claims in the Aqueous Film-Forming Foam (AFFF) multi-district litigation. The settlement involves approximately 115,000 to 120,000 eligible plaintiffs and includes payments scheduled through 2034 to manage legacy litigation risks.
The Delaware Court of Chancery granted a temporary restraining order enjoining Destination XL Group (DXL) from terminating its merger agreement with FBB Holdings I, Inc. pending further expedited proceedings. FBB filed the lawsuit to prevent DXL from exercising its right to terminate the deal if it was not consummated by the October 30, 2026 deadline. DXL intends to vigorously defend against the claims and pursue its own counterclaims.
The Unified Patent Court (UPC) of the European Union ruled that Enanta's European Patent No. EP 4 051 265 is invalid, dismissing Enanta's patent infringement action against Pfizer. The lawsuit concerned Pfizer's manufacture and sale of Paxlovid in 18 EU member states. Enanta had sought a determination of liability for infringement, but the court found the infringement action unfounded following its decision on patent validity.
Zillow Group has entered into a stipulation of settlement to resolve a consolidated securities class action litigation (Jaeger v. Zillow Group, Inc.) for $212.5 million in cash. The company expects approximately $48 million of the settlement to be covered by insurance proceeds, with the remainder resolving claims related to stock purchases made between August 5, 2021, and November 2, 2021. The settlement is subject to preliminary and final court approval and contains no admission of liability or wrongdoing.
Counterparty
Jaeger v. Zillow Group, Inc., et al. (Class Action Plaintiffs)
Beneficient filed a motion to intervene in Delaware Court of Chancery litigation against HCLP Nominees, L.L.C. to invalidate approximately $130 million in purported debt and recover $211 million previously paid. The company alleges the debt was fabricated by former CEO Brad Heppner as part of a fraudulent scheme for which he was convicted in May 2026.
Counterparty
HCLP Nominees, L.L.C.
“Mr. Heppner’s fraud should not continue to burden Beneficient and its stockholders. We are executing the strategy we outlined in September and are pursuing a comprehensive resolution that allows the Company to move forward. We will continue to take the steps necessary to achieve the objectives of that strategy, including additional litigation, while we seek an acceptable consensual resolution. This filing advances our efforts by placing our claims before the Court and seeking relief from the ongoing harm Heppner is causing. Our focus remains on strengthening Beneficient’s financial position and enabling the business to realize its potential.”
Kinetik Holdings subsidiary EagleClaw Midstream Ventures reached a settlement with Energy Transfer to resolve a dispute regarding the expiration date of an NGL purchase agreement. The parties confirmed the agreement will terminate on December 31, 2026, while a second agreement remains subject to ongoing litigation awaiting adjudication.
CV Sciences has settled an arbitration case initiated in February 2025 against its former legal counsel. Under the settlement terms, the company received $500,000 and both parties have mutually released all claims against each other.
Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.
BDR Pharmaceuticals has filed a lawsuit against the FDA challenging the agency's decision to grant Phathom's VOQUEZNA (vonoprazan) 10 years of NCE exclusivity through May 2032. BDR alleges the FDA improperly applied the GAIN Act to extend this exclusivity, which currently prevents the FDA from receiving abbreviated new drug applications (ANDAs) for generic versions of the drug. Phathom intends to take action to protect its statutory exclusivities and believes the FDA's prior ruling was correct.
Onity Group Inc. filed a declaratory judgment action in federal court seeking judicial clarification of a New York mortgage servicing regulation regarding optional expedited payment fees. The company is challenging the regulation's requirement that fees be "reasonably related to the cost of rendering that service," arguing the standard is undefined and lacks fair notice. This legal action follows ongoing discussions and information requests from New York regulators concerning the company's fee practices.
Counterparty
U.S. District Court for the Northern District of New York
The U.S. Court of Appeals for the Fifth Circuit vacated a lower court's order that had granted class certification in a securities class action against Filana Therapeutics. The appellate court ruled that the district court misapplied legal standards regarding market efficiency and 'meme-stock' dynamics, remanding the case for further proceedings.
Counterparty
U.S. District Court for the Western District of Texas
Curanex Pharmaceuticals disclosed two putative securities class action lawsuits filed in the Supreme Court of the State of New York related to its August 2025 IPO. The complaints allege material misstatements and omissions in the IPO offering documents regarding risks of stock-price manipulation and underwriter due diligence deficiencies. The company intends to defend the actions vigorously and has received extensions to respond to the complaints through late 2026.
Collegium Pharmaceutical entered into a settlement agreement with Grünenthal GmbH to resolve patent infringement litigation related to Nucynta ER. As part of the settlement, Collegium will pay $17 million to terminate a 2015 license agreement and discharge all future royalty obligations. Additionally, Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the pending lawsuit.
ZoomInfo Technologies Inc. has entered into a memorandum of understanding to settle a putative securities class action lawsuit for $44 million. The settlement, which is subject to court approval, resolves allegations that the company made false or misleading statements regarding its business and operations between 2020 and 2024. A portion of the payment is expected to be covered by insurance, though the settlement does not resolve other related derivative or direct investor lawsuits.
Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.
Rekor Systems filed a verified complaint in the Delaware Court of Chancery against former director Viraj Mehta, alleging a breach of his fiduciary duty of loyalty. The lawsuit relates to the company's December 2025 financing with a hedge fund and seeks compensatory damages, restitution of director compensation, and disgorgement.
Counterparty
Viraj Mehta
“Our Board took this action after months of careful investigation. Directors have a fundamental obligation to provide complete and candid information when critical financing decisions are being made. We believe the facts warrant judicial review, and we intend to pursue the Company's claims and every appropriate remedy available to protect Rekor and its shareholders.”
Robert A. Berman, Chairman and Chief Executive Officer
“This is a first step, not the end of our review. We continue to examine unusually high stock-borrow utilization rates, other unusual activity in Rekor common stock, and relevant financing and ownership matters. We will follow the evidence wherever it leads. Access to capital should not come at the expense of market integrity, corporate governance or the rights of public shareholders.”
Robert A. Berman, Chairman and Chief Executive Officer
Conduent Incorporated entered into an $80 million class action settlement agreement to resolve consolidated litigation pending in the U.S. District Court for the District of New Jersey. The lawsuit stems from a previously disclosed January 2025 cybersecurity incident, and the settlement amount covers class member recovery, monitoring costs, and legal fees. The agreement is subject to court approval and is expected to be covered by the company's cyber insurance.
Counterparty
Plaintiffs in In re: Conduent Business Services Data Breach Litigation
Brand Engagement Network Inc. entered into a Settlement and Forbearance Agreement with Evora Partners, LLC to resolve a breach of contract lawsuit filed in the Southern District of New York. The company agreed to pay a discounted settlement amount of $825,000 to resolve approximately $1.3 million in outstanding consulting fees, with payments scheduled in installments through December 2026.
The Illinois Commerce Commission approved a settlement agreement regarding Nicor Gas' general base rate case, authorizing an annual base rate revenue increase of approximately $82 million. The agreement, effective November 16, 2026, includes a 9.48% return on equity and requires Nicor Gas to dismiss its pending appeal of a previous 2025 rate case decision.
Xeris Biopharma Holdings filed patent infringement lawsuits in the U.S. District Court for the District of New Jersey against several pharmaceutical companies regarding its KEVEYIS® (dichlorphenamide) product. The lawsuits allege infringement of U.S. Patent No. 12,758,502 and seek injunctive relief and monetary damages to prevent the defendants from marketing generic versions of the drug.
United Therapeutics entered into a comprehensive settlement agreement with Liquidia Technologies to resolve multiple patent infringement and trade secret lawsuits. Liquidia will pay United Therapeutics $330.4 million in damages and has agreed to remove the PH-ILD indication from its Yutrepia product labeling, while United Therapeutics will pay Liquidia $10.0 million to resolve separate infringement claims.